Last year, Smith & Nephew PLC generated 1.07B USD for its biggest-performing segment, Sports Medicine Joint Repair. The United States of America made the largest contribution, accounting for 3.31B USD last year. For the latest quarter, Smith & Nephew PLC reported the revenue of 300.00M USD for the period ending 2026-06-27, which came from the top-performing segment, Advanced Wound Care. United States of America contributed the highest revenue, at 816.00M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Sports Medicine Joint Repair

Knee Implants

Advanced Wound Care

Trauma & Extremities

Arthroscopic Enabling Technologies

Hip Implants

Advanced Wound Bioactives

Advanced Wound Devices

ENT (Ear, Nose and Throat)

Other Surgical Businesses

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Sports Medicine Joint Repair

1.07B(17.31%)

982.00M(16.90%)

945.00M(17.03%)

870.00M(16.68%)

839.00M(16.10%)

710.00M(15.57%)

794.00M(15.45%)

697.00M(14.21%)

Knee Implants

1.01B(16.40%)

947.00M(16.30%)

940.00M(16.94%)

899.00M(17.24%)

876.00M(16.81%)

822.00M(18.03%)

1.04B(20.28%)

1.02B(20.74%)

Advanced Wound Care

766.00M(12.43%)

735.00M(12.65%)

725.00M(13.07%)

712.00M(13.65%)

731.00M(14.03%)

647.00M(14.19%)

714.00M(13.90%)

740.00M(15.09%)

Trauma & Extremities

649.00M(10.53%)

608.00M(10.46%)

564.00M(10.16%)

543.00M(10.41%)

576.00M(11.05%)

460.00M(10.09%)

488.00M(9.50%)

493.00M(10.05%)

Arthroscopic Enabling Technologies

647.00M(10.50%)

632.00M(10.88%)

588.00M(10.60%)

567.00M(10.87%)

590.00M(11.32%)

517.00M(11.34%)

591.00M(11.50%)

600.00M(12.23%)

Hip Implants

641.00M(10.40%)

619.00M(10.65%)

599.00M(10.79%)

584.00M(11.20%)

612.00M(11.74%)

567.00M(12.43%)

613.00M(11.93%)

613.00M(12.50%)

Advanced Wound Bioactives

621.00M(10.07%)

581.00M(10.00%)

553.00M(9.97%)

520.00M(9.97%)

496.00M(9.52%)

431.00M(9.45%)

424.00M(8.25%)

320.00M(6.53%)

Advanced Wound Devices

406.00M(6.59%)

365.00M(6.28%)

328.00M(5.91%)

280.00M(5.37%)

269.00M(5.16%)

232.00M(5.09%)

242.00M(4.71%)

215.00M(4.38%)

ENT (Ear, Nose and Throat)

220.00M(3.57%)

210.00M(3.61%)

196.00M(3.53%)

153.00M(2.93%)

131.00M(2.51%)

106.00M(2.32%)

151.00M(2.94%)

--(--)

Other Surgical Businesses

136.00M(2.21%)

131.00M(2.25%)

111.00M(2.00%)

87.00M(1.67%)

92.00M(1.77%)

68.00M(1.49%)

79.00M(1.54%)

209.00M(4.26%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States of America

Other Established Markets

Emerging &internatiuonal market

United Kingdom

China

Other

Established Markets

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

United States of America

3.31B(53.63%)

3.12B(53.75%)

2.98B(53.69%)

2.76B(53.00%)

2.66B(51.00%)

2.34B(51.29%)

2.55B(49.65%)

2.35B(48.00%)

2.33B(48.94%)

2.30B(49.24%)

2.22B(47.84%)

2.01B(43.58%)

1.86B(42.79%)

1.65B(39.91%)

1.76B(41.12%)

Other Established Markets

1.48B(24.03%)

1.27B(21.88%)

1.14B(20.45%)

999.00M(19.16%)

1.10B(21.05%)

966.00M(21.18%)

1.08B(21.08%)

1.48B(30.22%)

--(--)

1.71B(41.24%)

1.77B(41.43%)

Emerging &internatiuonal market

1.00B(16.27%)

980.00M(16.87%)

959.00M(17.28%)

947.00M(18.16%)

916.00M(17.57%)

771.00M(16.91%)

957.00M(18.63%)

857.00M(17.48%)

--(--)

677.00M(14.66%)

563.00M(12.94%)

483.00M(11.68%)

454.00M(10.63%)

United Kingdom

246.00M(3.99%)

226.00M(3.89%)

201.00M(3.62%)

186.00M(3.57%)

189.00M(3.63%)

166.00M(3.64%)

211.00M(4.11%)

211.00M(4.30%)

244.00M(5.12%)

266.00M(5.70%)

301.00M(6.50%)

299.00M(6.48%)

293.00M(6.73%)

297.00M(7.18%)

291.00M(6.81%)

China

128.00M(2.08%)

210.00M(3.61%)

275.00M(4.96%)

319.00M(6.12%)

352.00M(6.75%)

318.00M(6.97%)

336.00M(6.54%)

--(--)

Other

--(--)

2.19B(45.94%)

2.10B(45.06%)

2.12B(45.66%)

--(--)

Established Markets

--(--)

1.63B(35.28%)

1.63B(37.53%)

--(--)